As Dew pointed out, currently Lovenox dominates the market.
As I see it, Polymedix has two choices - develop the drug for the entire market, or partner with one of the also-rans who can then sell against Lovenox with the claim that "their" LMWH is now reversible. (In fact all of them would be reversible with the same drug, but the others would possibly be off-label in that the trials would only have been with the partnered product).
If one of the also-rans could grab even 10% more of the market because of partnering with Polymedix, that would be serious money. (Right now, my understanding is that all the LMWHs are pretty much fungible, and Lovenox's dominance comes from marketing not fundamentals. Dew follows this market much more closely than I, so maybe he could comment if this is correct or not).
why "healthy subjects" would risk being injected with tinzaparin
Same as any trial - they get paid. Risk here is minimal from the Tinzaparin as its a known quantity. Any real risk comes from the Polymedix drug simply because it hasn't been in very many humans, and stuff happens in Phase I trials.
Market Data 
Markets 
AI
